JP2020528457A5 - - Google Patents

Info

Publication number

JP2020528457A5

JP2020528457A5 JP2020526666A JP2020526666A JP2020528457A5 JP 2020528457 A5 JP2020528457 A5 JP 2020528457A5 JP 2020526666 A JP2020526666 A JP 2020526666A JP 2020526666 A JP2020526666 A JP 2020526666A JP 2020528457 A5 JP2020528457 A5 JP 2020528457A5

Authority

JP

Japan

Prior art keywords

endostatin

composition

chemotherapeutic agent

cancer

dna double

Prior art date

2018-07-27

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Granted

Links

• Espacenet
• Global Dossier
• Discuss

• 206010028980 Neoplasm Diseases 0.000 claims description 79
• 108010079505 Endostatins Proteins 0.000 claims description 74
• 210000004027 cell Anatomy 0.000 claims description 48
• 102100031162 Collagen alpha-1(XVIII) chain Human genes 0.000 claims description 47
• 239000002246 antineoplastic agent Substances 0.000 claims description 40
• 229940127089 cytotoxic agent Drugs 0.000 claims description 39
• 201000011510 cancer Diseases 0.000 claims description 38
• 230000005782 double-strand break Effects 0.000 claims description 38
• 101500026378 Homo sapiens Endostatin Proteins 0.000 claims description 30
• 230000001939 inductive effect Effects 0.000 claims description 27
• AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 26
• LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 26
• NBBJYMSMWIIQGU-UHFFFAOYSA-N Propionic aldehyde Chemical compound CCC=O NBBJYMSMWIIQGU-UHFFFAOYSA-N 0.000 claims description 26
• 229940079593 drug Drugs 0.000 claims description 17
• 239000003814 drug Substances 0.000 claims description 17
• 239000008194 pharmaceutical composition Substances 0.000 claims description 17
• 238000011269 treatment regimen Methods 0.000 claims description 15
• 241000588724 Escherichia coli Species 0.000 claims description 13
• 125000003172 aldehyde group Chemical group 0.000 claims description 13
• 150000001413 amino acids Chemical class 0.000 claims description 13
• ZTQSAGDEMFDKMZ-UHFFFAOYSA-N butyric aldehyde Natural products CCCC=O ZTQSAGDEMFDKMZ-UHFFFAOYSA-N 0.000 claims description 13
• 229960004679 doxorubicin Drugs 0.000 claims description 13
• VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical group COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims description 13
• 229960005420 etoposide Drugs 0.000 claims description 13
• WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims description 13
• 201000001441 melanoma Diseases 0.000 claims description 13
• 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 13
• 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 13
• 238000011282 treatment Methods 0.000 claims description 11
• 210000004881 tumor cell Anatomy 0.000 claims description 11
• 238000011287 therapeutic dose Methods 0.000 claims description 8
• 238000011285 therapeutic regimen Methods 0.000 claims description 8
• 238000001959 radiotherapy Methods 0.000 claims description 5
• 230000001225 therapeutic effect Effects 0.000 claims description 4
• 230000006907 apoptotic process Effects 0.000 claims description 3
• 239000012472 biological sample Substances 0.000 claims description 3
• 239000003795 chemical substances by application Substances 0.000 claims description 3
• 238000000338 in vitro Methods 0.000 claims description 3
• 238000001727 in vivo Methods 0.000 claims description 3
• 102100022204 DNA-dependent protein kinase catalytic subunit Human genes 0.000 claims description 2
• 101710157074 DNA-dependent protein kinase catalytic subunit Proteins 0.000 claims description 2
• 239000003937 drug carrier Substances 0.000 claims description 2
• 230000000694 effects Effects 0.000 claims description 2
• 230000002401 inhibitory effect Effects 0.000 claims description 2
• 239000000203 mixture Substances 0.000 claims 40
• 230000002950 deficient Effects 0.000 claims 4
• 230000001419 dependent effect Effects 0.000 claims 1
• 239000000890 drug combination Substances 0.000 claims 1
• 230000002708 enhancing effect Effects 0.000 claims 1
• 238000000034 method Methods 0.000 description 41
• 102000002045 Endothelin Human genes 0.000 description 10
• 108050009340 Endothelin Proteins 0.000 description 10
• ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 description 10
• 238000004519 manufacturing process Methods 0.000 description 2
• 229940044683 chemotherapy drug Drugs 0.000 description 1
• 230000001678 irradiating effect Effects 0.000 description 1
• 238000002483 medication Methods 0.000 description 1
• 230000035945 sensitivity Effects 0.000 description 1